Changes in global patterns of care for first-line advanced nonsquamous (NS) non-small cell lung cancer (NSCLC): 2007-2010

被引：0
|
作者：
Combest, A. J.
Bryan, J. K.
Moseley, A.
Reitsma, D. J.
Scazafave, M.
Wood, J. M.
Iocca, H. A.
Goyo, J.
An, J. S.
Lee, M. W.
机构：
[1] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA
[2] PPD Inc, Wilmington, NC USA
[3] Synovate Healthcare, Mahwah, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e16639
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16639
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Faehling, M.
    Achenbach, J.
    Staib, P.
    Steffen, U.
    Tessen, H. W.
    Brugger, W.
    ANNALS OF ONCOLOGY, 2016, 27
  • [42] Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Han, B.
    Chu, T.
    Zhang, X.
    Zhong, H.
    Zhang, B.
    Wang, H.
    Gu, A.
    Zhang, W.
    Shi, C.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S398 - S398
  • [43] Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
    M. Faehling
    J. Achenbach
    P. Staib
    U. Steffen
    H. W. Tessen
    V. E. Gaillard
    W. Brugger
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 1375 - 1383
  • [44] Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Shi, C.
    Zhong, H.
    Zhang, W.
    Zhang, B.
    Zhong, R.
    Zhang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S646 - S647
  • [45] First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses
    Gettinger, S. N.
    Hellmann, M. D.
    Shepherd, F. A.
    Antonia, S. J.
    Brahmer, J.
    Chow, L. Q.
    Goldman, J.
    Juergens, R.
    Borghaei, H.
    Ready, N. E.
    Gerber, D. E.
    Nathan, F.
    Shen, Y.
    Harbison, C. T.
    Rizvi, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S632 - S632
  • [46] Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Faehling, M.
    Achenbach, J.
    Staib, P.
    Steffen, U.
    Tessen, H. W.
    Gaillard, V. E.
    Brugger, W.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (07) : 1375 - 1383
  • [47] Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer
    Kish, Jonathan
    Liassou, Djibril
    Hartman, John
    Lubinga, Solomon J.
    Chopra, Dhruv
    Feinberg, Bruce
    AMERICAN JOURNAL OF MANAGED CARE, 2023, 29 (05): : E129 - E135
  • [48] The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
    Spagnuolo, Alessia
    Gridelli, Cesare
    CANCERS, 2023, 15 (08)
  • [49] Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer
    Yang, Szu-Chun
    Ou, Huang-Tz
    Su, Wu-Chou
    Wang, Shi-Yi
    CANCER MEDICINE, 2023, 12 (07): : 8838 - 8850
  • [50] Immunological and nutritional predictors for first-line chemoimmunotherapy in advanced non-small cell lung cancer
    Takeda, Takayuki
    Ogura, Yuri
    Kataoka, Nobutaka
    Kunimatsu, Yusuke
    Tachibana, Yusuke
    Sugimoto, Takumi
    Tani, Nozomi
    Sato, Izumi
    Hirose, Kazuki
    Kato, Daishiro
    ANNALS OF ONCOLOGY, 2021, 32 : S334 - S334
12345